Midkine Deficiency Attenuates Lipopolysaccharide-Induced Pulmonary Inflammation

Area of Science:

• Pulmonary Medicine
• Immunology
• Molecular Biology

Background:

• Midkine (MDK) is a growth factor involved in cell regulation and inflammatory diseases.
• The specific role of MDK in lung inflammation remains largely unknown.

Purpose of the Study:

• To investigate the role of Midkine (MDK) in lipopolysaccharide (LPS)-induced pulmonary inflammation.
• To elucidate the mechanisms by which MDK influences lung inflammatory responses.

Main Methods:

• Utilized a mouse model of LPS-induced pulmonary inflammation, comparing wild-type and MDK-deficient mice.
• Analyzed inflammatory parameters in bronchoalveolar lavage fluid and lung tissues.
• Conducted in vitro experiments using human bronchial epithelial cells and MDK knockdown via siRNA.

Main Results:

• LPS administration increased MDK expression in wild-type mouse lungs.
• MDK-deficient mice exhibited significantly reduced inflammatory cell counts, protein levels, and chemokine concentrations (KC, MIP-2) in BALF.
• MDK deficiency led to lower mRNA expression of TNF-α, KC, and MIP-2, and reduced lung inflammation scores.
• In vitro, MDK knockdown attenuated LPS-induced upregulation of TNF-α and CXCL8 in bronchial cells.

Conclusions:

• Midkine (MDK) deficiency attenuates LPS-induced pulmonary inflammation.
• MDK appears to promote lung inflammation by upregulating inflammatory cytokines and chemokines.
• These findings highlight MDK as a potential therapeutic target for pulmonary inflammatory conditions.